Literature DB >> 27165535

The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents.

Melissa Jean1, Arvind Raghavan2, Matthew L Charles3, Mark S Robbins4, Eric Wagner1, Georges-Étienne Rivard5, Xavier Charest-Morin1, François Marceau6.   

Abstract

AIMS: The isolated human umbilical vein is a robust contractile bioassay for ligands of the bradykinin (BK) B2 receptor (B2R), also extendable to B1 receptor (B1R) pharmacology. We hypothesized that, as a freshly isolated vessel, it also contains traces of plasma proteins that may confer responses to exogenous proteases via the formation of kinins. MAIN
METHODS: Rings of human umbilical veins were mounted in organ baths containing Krebs buffer maintained at 37°C and purified proteases were introduced in the bathing fluid along with additional drugs/proteins that permit mechanistic analysis of effects. KEY
FINDINGS: The previously described contractile response to human recombinant tissue kallikrein (KLK-1, 1-10nM) is not influenced by metabolic inhibitors, suggesting its dependence on a preexisting reservoir of low molecular weight-kininogen (LK). Active plasma kallikrein (apK, ≤5nM) was inactive in fresh tissues, unless high molecular weight-kininogen (HK, 39-197nM) replenishment was applied. The effects of KLK-1 and HK+apK are abolished by pretreating tissues with icatibant, but not with tranexamic acid. C1-esterase inhibitor inhibited only HK+apK. Purified plasmin and neutrophil proteinase-3 produced small contractions in the presence of HK only, and tissue plasminogen activator, none. B1R stimulation was pharmacologically evidenced in response to KLK-1 if LK was supplied. SIGNIFICANCE: The pharmacology of KLK-1 and HK+apK in the human isolated umbilical vein is essentially based on the activity of locally generated kinins and this assay models the inhibitory action of some therapeutic agents active in angioedema states. Proteases that indirectly generate kinins have little activity in the system.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bradykinin B(2) receptor; Plasma kallikrein; Plasmin; Tissue kallikrein

Mesh:

Substances:

Year:  2016        PMID: 27165535     DOI: 10.1016/j.lfs.2016.05.010

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Structure-Based Design and Synthesis of a New Phenylboronic-Modified Affinity Medium for Metalloprotease Purification.

Authors:  Shangyong Li; Linna Wang; Ximing Xu; Shengxiang Lin; Yuejun Wang; Jianhua Hao; Mi Sun
Journal:  Mar Drugs       Date:  2016-12-27       Impact factor: 5.118

2.  Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B2 receptor and peptidase resistance in rats.

Authors:  Xavier Charest-Morin; Hélène Bachelard; Melissa Jean; Francois Marceau
Journal:  PeerJ       Date:  2017-01-18       Impact factor: 2.984

Review 3.  Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?

Authors:  Márta L Debreczeni; Zsuzsanna Németh; Erika Kajdácsi; Henriette Farkas; László Cervenak
Journal:  Clin Rev Allergy Immunol       Date:  2021-03-16       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.